SIL maintenance therapy for multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a maintenance treatment called SIL for multiple myeloma patients who have responded well to a stem cell transplant. It may help keep the cancer in remission for longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma confirmed by a doctor.
- You must be 18 years or older.
- You must have had a stem cell transplant and your disease responded to it (partial response or better).
- You must not have an active infection that needs treatment within the last 14 days.
- You must not have unstable heart, liver, kidney, or other serious health conditions.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called selinexor (KPT-330) combined with various standard treatments for patients whose multiple myeloma has come back or stopped responding to therapy. The goal is to see if adding selinexor helps control the cancer better than current options, and to find the safest dose for different drug pairings.
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
This Phase 2 trial studies a treatment called SVRd in people newly diagnosed with multiple myeloma that has spread to areas outside the bone (called extramedullary disease). It aims to see how well the treatment works and whether it is safe for this specific group.
This trial tests if the drug selinexor can help prevent multiple myeloma from coming back after CAR-T cell therapy. It is for people with high-risk or persistent myeloma who have already received a specific CAR-T treatment called Carvykti.
This early-phase study looks at whether it’s safe to stop the usual “maintenance” medicine after a strong response in multiple myeloma. It aims to see if stopping treatment for people with very low remaining disease reduces drug exposure without allowing relapse too soon.
This trial studies whether adding low-dose lenalidomide to ixazomib can help keep high-risk multiple myeloma from coming back after initial treatment. It may help prolong the time before the disease worsens, while also checking side effects.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.